Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCCH1903 Atezolizumab in relapsed/refractory extranodal NK/T-cell lymphoma
jRCT2031190177Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) and extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Objective response rate (independent review). Started Jul 2020; status: completed.
02
Drugs
atezolizumab
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on jRCT2031190177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190177.